Research programme: tyrosine kinase inhibitors - LEO PharmaAlternative Names: LEO-A
Latest Information Update: 29 Mar 2010
At a glance
- Originator LEO Pharma
- Mechanism of Action Phosphotransferase inhibitors; Platelet-derived growth factor inhibitors; Raf kinase inhibitors; Src-Family kinase inhibitors; Vascular endothelial growth factor receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours